Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*--Addressing Nationwide Shortage of the Essential Drug

Ritedose has the largest portfolio of nebulizer products, with new dosage completing the company's portfolio of albuterol treatments COLUMBIA, S.C., May 20, 2025 /PRNewswire/ -- Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract...